Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

Richard Keefe, Ph.D.
Duke University Medical Center
Durham, North Carolina, USA
Financial Disclosures
Past 3 Years

Consultant/Ad Board/Service Provider for: Abbvie, Akebia, Amgen, Asubio, AviNeuro/ChemRar, Biogen Idec, BiolineRx, Biomarin, Boehringer-Ingelheim, Eli Lilly, EnVivo/FORUM, GW Pharmaceuticals, Lundbeck, Merck, Minerva Neuroscience Inc., Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Takeda, Targacept

Research Funding: NIMH, Singapore Medical Research Council, Columbia University Foundation for Mental Hygiene, GlaxoSmithKline, PsychoGenics, Novartis, Brain Plasticity Institute

Investment: Founder of NeuroCog Trials, Inc., which provides rater training, data quality assurance and consultation to several pharmaceutical companies and other consortia. Investor in Sengenix, Inc. but do not do any work related to this company.

Royalties: Brief Assessment of Cognition in Schizophrenia (BACS), MATRICS Consensus Cognitive Battery (MCCB), Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
Background

• There are currently no treatments approved for the treatment of cognitive impairment in schizophrenia (CIAS)

• Significant ongoing treatment development holds promise for an approved drug for CIAS before the end of this decade
Background

• The assessment of cognition in patients with schizophrenia is not a standard component of education in psychiatry

• When treatments for CIAS become available, it will be essential for treating psychiatrists and others involved in prescribing medications to evaluate whether their patients are responsive to treatment

• Yet there are many challenges to the evaluation of treatment response for CIAS
Aims of the Meeting

• To reach consensus on:
  – 1) methods for monitoring response to procognitive medications and interventions for patients with schizophrenia;
  – 2) the necessary tools and training to conduct this assessment in the clinic setting; and
  – 3) approaches to prescribing procognitive medications and interventions in the clinic.
Steering Committee

• George Haig, co-chair
• Richard Keefe, co-chair
• Steve Marder
• Phil Harvey
• Eduardo Dunayevich
• Ilise Lombardo
• Alice Medalia
• Michael Davidson
Survey Methods

- Survey questions were developed by the Steering Committee and sent to 46 experts in schizophrenia, cognition, clinical trials, community psychiatry, and drug development
- Thirty-four (73%) respondents completed the survey.
- A small number of questions were not clearly understood based on comments from the experts and their data were disregarded.
- Several questions revealed existing consensus and were not discussed further.
- Most questions revealed significant disagreement or divergence of opinions, and were the focus of discussion at this meeting.
Discussion Process

• A group of 23 academic and industry experts in cognition, schizophrenia, community psychiatry, and drug development were selected from the pool of 46 experts who completed the survey and invited to participate as panelists at the consensus meeting.

• The consensus meeting was open to 70 audience participants who were interested in the discussion.
Panelists

Chris Bowie, PhD
Robert Buchanan, MD
Dragana Bugarski-Kirola, MD
William Carpenter, MD
John Csernansky, MD
Pedro Dago, MD
Eduardo Dunayevich, MD
Dante Durand, MD
Fred Frese, PhD
Donald Goff, MD
Jim Gold, PhD
George Haig, PharmD
Christine Hooker, PhD

Queens University, Toronto
University of Maryland
Roche
University of Maryland
Northwestern Univ Feinberg School of Medicine
Northwestern Univ Feinberg School of Medicine
Amgen
University of Miami
Northeast Ohio Medical University
Nathan Kline Institute
University of Maryland, Baltimore
AbbVie
Harvard University
Panelists

Richard Keefe, PhD
Alex Kopelowicz, MD
Tony Loebel, MD
Stephen Marder, MD
Susan McGurk, PhD
Alice Medalia, PhD
Lewis Opler, MD, PhD
Amy Pinkham, PhD
Robert Stern, MD

Duke University Medical Center
Semel Institute for Neuroscience
Sunovion
Semel Institute at UCLA
Dartmouth Medical School
Columbia University
Columbia University Medical Center
Southern Methodist University
Essex County Hospital Center
Meeting Structure and Process

• Brief description, including pros and cons, of several cognitive assessment methods to ground panelists in their understanding of relevant tools

• Very brief presentations where speakers were asked to argue on opposing sides of an issue or question, followed by extensive discussion by all panelists

• All of the questions that were discussed and debated during the conference were posed to the panelists for a final vote, and their responses were recorded with an audience response system

• Included in the voting process was a rank ordering of preferred method for assessing cognition in the office setting

• The audience participants were asked to record their responses on paper and were collected following the meeting
Methods of Assessment

- Comprehensive cognitive performance assessment (1-2 hours)
- Brief cognitive performance assessment
  - 15-30 mins; 10 mins; 5 mins
- Interview-based measures of cognition
- Interview-based assessment of real-world functioning
- Performance-based measures of functional capacity
Conclusions

• Both cognition and functioning are important in the evaluation of efficacy for a cognitive-enhancing treatment
• No consensus was reached on whether the impracticality of formal assessments of cognition outweighs their validity for monitoring treatment in clinical practice
• Strong consensus that clinicians can assess response if they have frequent contact with the patient and that patient interviews alone are not sufficient
• The role of informants is important, but depends upon the frequency of contact between patient and clinicians
• There was no consensus on the best methods for assessing treatment response, although brief performance-based cognitive assessments, interview-based assessments, and performance-based measures of functional capacity were viewed as slightly more favorable
The impracticality of formal assessments of cognition outweighs their validity for monitoring treatment in clinical practice.
1. Patient interviews are sufficient to assess response

**Mean: 5.1**
2. Informants (caregiver/family/employer) are vital to the assessment of response.
3. A high-contact clinician can determine response based on regular examinations
Weighted Evaluation of Assessment Methods

- Brief (15-30 m)
- Performance-Based Measure of Functional Capacity
- Briefer (< 10 min)
- Interview Based Measure of Cognition
- Very Brief (< 5 min)
- Self-Administered
- Comprehensive (1-2 h)
Conclusions: Patient Selection

• There was clear consensus that age and duration of illness should not be a consideration in patient selection for procognitive treatments. However, if resources are limited the participants viewed younger and less chronic patients as a priority.

• Which patients receive treatment should not depend upon their baseline level of cognitive impairment or their opportunity to improve functionally.
Conclusions: Positive Symptom Concerns

• Treatment can be initiated in a patient population that is likely to respond to treatment, with or without the presence of low-moderate or relatively unstable positive symptoms

• Procognitive medications need not be discontinued during periods of acute exacerbation of psychosis.
Conclusions: Cognitive Remediation

• Cognitive remediation is likely to facilitate and potentially enhance a drug treatment benefit.
• However, cognitive remediation should not be required for drug treatment to be initiated.
• Drug companies and other developers of procognitive medications should study the additive benefits of cognitive remediation and other nonpharmacological treatments in the development of procognitive medications, and data should be published or included in product labeling.
SUPPORTIVE DATA SLIDES
1. Efficacy is defined as improvement in cognition
2. Efficacy is defined as functional improvement
Comprehensive Batteries (Keefe)

- Many different domains of cognitive impairment in schizophrenia
  - MATRICS group chose 7 of them for a *clinical trials battery*
- Patients with schizophrenia vary greatly in their profile and severity of their cognitive impairment
- What aspect of cognition is improving (or getting worse!) with treatment is tremendously important clinical information
- Clinical response is difficult to detect and depends heavily on the test-retest reliability of the measure
  - 90% Reliable Change Index of MCCB composite score with test-retest reliability of .90 is 10 points!
- Sensitive assessment needs to be broad and deep
Validated Brief Assessments (Gold)

• **30 minute tools:**
  – RBANS
  – BACS

• **10-15 minute tools—none have RCIs:**
  – BNA, Fervaha, 2014: LNS + Dig Sym
  – BCATS, Hurford, (2011): TMTB, Fluency, Dig Sym

• “If you sacrifice reliability for testing time, the consequence is that even larger changes will be needed to be considered beyond chance, and that won’t happen very often, so even a drug with significant benefits will look like a failure.”
1. Mediate the cognition – functioning relationship

1. Easy to administer, well tolerated

1. Very good psychometric properties (comparable to cognition)

1. Superior to cognition for predicting independent living and work

1. Indirect relationship to cognitive change

1. Issues with cultural adaptability?*

1. Intrapsychical, Intersubjective, and Extrapsychical factors limit the relationship with actual community functioning

1. No direct assessment of work*
Community Functioning (Harvey)

• Domains of Community Functioning
  – Social
  – Vocational/Productive
  – Residential/Self Care

• Assessment Strategies
  – Self Report
  – Informants/Observers/Clinician
  – Record/Archives
Patient/Care-giver/Staff assessment (Marder)

• Strengths
  • Describes functioning in real world
  • Cognition and functional capacity measures are only weakly related to real world functioning
  • Data from SCoRS and other instruments indicates Care-giver information is valuable – perhaps more than pt information
  • Patients may appreciate changes in cognition that do not translate to functioning

• Limitations
  • Other informants may not be available
  • Informants may have agendas
  • Patients – and others – can not reliably compare their cognition with that of others.
Formal Assessments Are Necessary (Hooker)

• Self-report susceptible to bias
• Formal assessment is objective
  – Performance assessment more reliable
  – Standardized criteria for cognitive improvement
  – Sensitive to cognitive change
• Tests measure different cognitive processes
  – target & assess specific neurocognitive systems
• Feasible
  – Web-based tools
<table>
<thead>
<tr>
<th>Test Name</th>
<th>Description</th>
<th>Estimated Time</th>
<th>Social Share Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>What You Value</td>
<td>This test looks at how much you prefer to invest in the present, future, yourself, or other people.</td>
<td>12 minutes</td>
<td>Facebook, Twitter</td>
</tr>
<tr>
<td>Personality and Emotion</td>
<td>This test looks at three different aspects of your daily emotions and personality.</td>
<td>15 minutes</td>
<td>Facebook, Twitter</td>
</tr>
<tr>
<td>Matching Faces In Photographs</td>
<td>These tests look at how good you are at matching two photographs of the same person.</td>
<td>20 minutes</td>
<td>Facebook, Twitter</td>
</tr>
<tr>
<td>Famous Faces</td>
<td>Face recognition can be surprisingly difficult - can you identify famous people from their faces?</td>
<td>5 minutes</td>
<td>Facebook, Twitter</td>
</tr>
</tbody>
</table>
1. Treatment of cognitive impairment in clinical practice should be initiated independent of a patient’s age and chronicity.
2. If age and chronicity are considered, should treatment of cognitive impairment in clinical practice focus on younger, less chronic patients or older, more chronic patients?
1. Treatment of cognitive impairment in clinical practice should be initiated independent of a patient’s level of cognitive impairment.
2. If baseline level of cognitive impairment is considered, should treatment of cognitive impairment in clinical practice focus on less impaired patients or more impaired patients?
1. Treatment of cognitive impairment in clinical practice should be initiated independent of a patient’s baseline level of everyday functioning.
2. If baseline level of functioning is considered, should treatment of cognitive impairment in clinical practice focus on patients with lower or higher levels of everyday functioning?
1. Should medication treatment of cognitive impairment be restricted to patients whose positive symptoms are stable and low to moderate or be used in the broader population?
Use of Procognitive Medications with Non-Pharmacological Treatments

1. Cognitive remediation is likely to provide substantial benefits when using medications

Mean: 2.3
Use of Procognitive Medications with Non-Pharmacological Treatments

2. Non-pharmacological treatments are an essential component of cognitive enhancement.

[Bar chart showing percentages]
Use of Procognitive Medications with Non-Pharmacological Treatments

3. Requiring the addition of cognitive remediation to a prescription for a precognitive medication would discourage the use of these medications.